Table 1

 Subject characteristics

VariablePatients (n = 153)Controls (n = 87)p Value
Values are means (SD) unless stated otherwise.
*The mean daily dose of frusemide equivalent at enrolment is given.
ACEi, angiotensin converting enzyme inhibitor; AF, atrial fibrillation; AIIA, angiotensin II inhibitor; LVEDV, left ventricular end diastolic volume; LVEF, left ventricular ejection fraction; LVESV, left ventricular end systolic volume; NYHA, New York Heart Association functional class; pV˙o2, peak oxygen consumption; SR, sinus rhythm; V˙e/V˙co2 slope, slope relating ventilation to carbon dioxide production.
Age (years)66 (11)66 (11)0.52
Height (cm)172 (8)170 (10)0.31
Weight (kg)80.0 (15.2)74.2 (11.1)0.04
Body surface area (kg/m2)1.9 (0.2)1.8 (0.4)0.40
Rhythm (SR/AF)104/4987/0
    Frusemide (furosemide)*64.4 (26.2)
    ACEi/AIIA (%)88
    Spironolactone (%)22
    β Blocker (%)44
NYHA class I/II/III/IV (n)2/99/48/2
LVEF (%)34.9 (6.3)60.5 (6.4)<0.0001
LVEDV (ml)227 (72)99 (24)<0.0001
LVESV (ml)150 (59)39 (12)<0.0001
Exercise time (s)491 (212)818 (189)<0.0001
pV˙o2 (ml/kg/min)21.6 (5.6)35.2 (7.5)<0.0001
e/V˙co2 slope35.7 (8.1)27.0 (2.8)<0.0001